论文部分内容阅读
本文报道了静脉注射免疫球蛋白(IGIV)治疗免疫缺陷症病人是否会传播非甲非乙型肝炎的回顾性调查结果。对41例原发性免疫缺陷症病人进行随机双盲和交叉安全性试验。这些病人采用IGIV治疗,月剂量为400mg/kg体重,疗程为6～15个月,采用1批还原和烷基化IGIV,3批pH4.2处理的未经修饰的IGIV。输注IGIV前和输注后每月采集血清样品,测定乳酸脱氢酶(LDH)、血清谷草转氨酶(SGOT)和血清谷丙转氨酶(SGPT)。在排除了甲型肝炎、乙型肝炎及其他能引起SGPT水平升高的疾病后,连续两次试验(间隔2～6周)测定的
This article reports the results of a retrospective survey of whether intravenous immunoglobulin (IGIV) in patients with immunodeficiency can transmit non-A, non-B hepatitis. Forty-one patients with primary immunodeficiency syndrome were randomized double-blind and cross-safety studies. These patients were treated with IGIV at a monthly dose of 400 mg / kg body weight over a period of 6-15 months, using one batch of reduced and alkylated IGIV, three batches of non-modified IGIV treated at pH 4.2. Serum samples were collected monthly before and after infusion of IGIV, and lactate dehydrogenase (LDH), serum aspartate aminotransferase (SGOT) and serum glutamate aminotransferase (SGPT) were measured. After excluding Hepatitis A, Hepatitis B and other diseases that cause elevated SGPT levels, two consecutive trials (2 to 6 weeks apart)